Immunohistochemical Detection of ZAP-70 Protein and its Importance in the Diagnostics of B-CLL
Authors:
A. Urbánová 1; P. Janega 1,2; K. Masárová 3; Z. Štefániková 3; P. Babál 1
Authors place of work:
Ústav patologickej anatómie, Lekárska fakulta, Univerzita Komenského v Bratislave
1; Ústav normálnej a patologickej fyziológie, Slovenská akadémia vied, Bratislava
2; Klinika hematológie a tranfuziológie, Fakultná nemocnica s poliklinikou, pracovisko sv. Cyrila a Metoda, Bratislava, Slovenská republika
3
Published in the journal:
Čes.-slov. Patol., 45, 2009, No. 2, p. 40-45
Category:
Original Article
Summary
Chronic B-lymphocytic leukemia (B-CLL) is one of the most frequent diseases of the lymphatic system in adults. It is known for its variable course – from benign to prospectless forms. Reliable prognostic markers are needed to precify the diagnosis and the correct therapy. The ZAP-70 protein, as a prospective marker, can be highly expressed in leukemic cells of B-CLL patients. It is related to a worse prognosis requiring intense therapy from the beginning.
The present study includes 20 cases of bone marrow trephine biopsy from patients with diagnosed B-CLL and 20 control cases without neoplastic infiltration. The specimens were investigated with standard immunohistochemical technique and with the use of the amplification system (DakoCytomation©). The results were evaluated semiquantitatively as negative (less than 5 %), positive (above 30 %), and irregularly positive (5–30 % of positive leukemic cells) and consecutively correlated with clinical evaluation of prognosis of the patient. The evaluation of the positivity was controlled also by morphometric analysis by determination of the area of ZAP-70 positivity related to the whole area of nuclei in the section. In the control specimens the ZAP-70 positivity was restricted to T-lymphocytes only. The level of the nuclear positivity of ZAP-70 protein detected in transformed B-lymphocytes showed significant correlation with the worse or the better clinical prognosis, respectively. Cases with irregular positivity did not show unambiguous clinical correlation. The use of the amplification system allowed to apply lower concentration of the primary antibody, reduction of background staining and increased the contrast of the findings leading to reduction of irregularly positive cases from 30 % (with routine histochemistry) to 10 %. It can be concluded that ZAP-70 represents a valuable prognostic marker for the chronic B-lymphocytic leukemia. Its evaluation by histochemistry is a suitable method for clinical praxis. Problematic may be the evaluation of borderline irregularly positive cases, in which the use of the histochemical amplification system is helpful. Strictly determined criteria are needed for limitation of inaccurate interpretation of the results.
Key words:
chronic B-lymphocytic leukemia – ZAP-70 – prognosis – immunohistochemistry
Zdroje
1. Abbott, B.L.: Advances in the diagnosis and treatment of chronic lymphocytic leukemia. Clin.Adv.Hematol.Oncol., 2, 2004, s. 448–454.
2. Admirand, J.H., Rassidakis, G.Z., Abruzzo, L.V., Valbuena, J.R., Jones, D., Medeiros, L.J.: Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma. Modern Pathology, 17, 2004, s. 954–961.
3. Bogner, C., Sandherr, M., Perker, M. et al.: Cyclin E but not bcl-2, bax or mcl-1 is differentially expressed in ZAP 70-positive and ZAP 70-negative B-CLL cells. Ann. Hematol., 85, 2006, s. 458–462.
4. Bojarska-Junak, A., Rolinski, J., Kawiak, J.: Modification of immunocytochemical ZAP-70 assay for potential clinical application in B-cell chronic lymphocytic leukemia. Folia Histochem. Cytobiol., 43, 2005, s. 19–23.
5. Castro, J.E., Prada, C.E., Loria O. et al.: ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia. Blood, 106, 2005, s. 2506–2512.
6. Catherwood, M.A., Matthews, C., Niblock, R., Dobbin, E., Morris, T.C., Denis Alexander H.: ZAP-70 mRNA quantification in B-cell chronic lymphocytic leukaemia. Eur. J. Haematol., 76, 2006, s. 294–298.
7. Chen, L., Widhopf, G., Huynh, L. et al.: Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood, 100, 2002, s. 4609-4614.
8. Chen, Z., Aston, E., Yu, M.K.: Loss of Zap-70 and low molecular weight phosphotyrosine phosphatase occurs after therapy in a patient with B-chronic lymphocytic leukemia. Leukemia, 19, 2005, s. 1503–1505.
9. Chevalier, P.: CD38 expression and secondary 17p deletion are important prognostic factors in chronic lymphocytic leukemia. Br. J. Haematol., 116, 2002, s. 142–150.
10. Gascoyne, R.D.: Hematopathology approaches to diagnosis and prognosis of indolent B-cell lymphomas. Hematology (Am.Soc.Hematol.Educ.Program), 2005, s. 299–306.
11. Gonzalez-Campos, J., Rios-Herranz, E., De Blas-Orlando, J.M., Martin-Noya, A., Parody-Ruiz-Berdejo, R., Rodriguez-Fernandez, J.M.: Chronic lymphocytic leukemia with two cellular populations: a biphenotypic or biclonal disease. Ann. Hematol., 74, 1997, s. 243-246.
12. Hahn, J.M.: Innere Medizin, 3.ed., Stuttgart: Georg Thieme Verlag, 2000, s. 556-557.
13. Hamblin, T.J., Orchard, J.A., Gardiner, A., Oscier, D.G., Davis, Z., Stevenson, F.K.: Immunoglobulin V genes and CD38 expression in CLL. Blood, 95, 2000, s. 2455-2457.
14. Kepley, C.L., Wilson, B.S., Oliver, J.M.: Identification of the Fc epsilonRI-activated tyrosine kinases Lyn, Syk, and Zap-70 in human basophils. J.Allergy Clin.Immunol., 102, 1998, s. 304–315.
15. Kim, S.Z., Chow, K.U., Kukoc-Zivojnov, N., et al.: Expression of ZAP-70 protein correlates with disease stage in chronic lymphocytic leukemia and is associated with, but not generally restricted to, non-mutated Ig VH status. Leuk.Lymphoma, 45, 2004, s. 2034–2045.
16. Krober, A., Bloehdorn, J., Hafner, S. et al.: Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. J.Clin.Oncol., 24, 2006, s. 969–975.
17. Laurenti, L., Petlickovski, A., Rumi, C. et al.: Comparison of ZAP-70/Syk mRNA levels with immunoglobulin heavy-chain gene mutation status and disease progression in chronic lymphocytic leukemia. Haematologica, 90, 2005, s. 1533–1540.
18. Mačák, J., Plank, L.: Ne-hodgkinské lmfomy (od Rappaporta po WHO 2001 a dnešek). Čes.-slov. Patol., 43, 2007, s. 39–49.
19. Müller-Hermelink, H.K., Catovsky, D., Montserrat, E., Harris, N.L.: Chronic lymphocytic leukaemia/small lymphocytic lymphoma. In: Jaffe, E.S., Harris, N.L., Stein, H., Vardiman, J.W., ed. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARCPress, 2001, s. 127–130.
20. Neil, E.K., Jelinek, D.F.: B-CLL: is the enigma of disease heterogeneity about to be revealed? Blood, 100, 2002, s. 1110–1111.
21. Plank, L.: Possibilities of the prognostic evaluation of lymph node biopsies in chronic lymphocytic leukemia of B origin. Bratisl.Lek.Listy, 82, 1984, s. 1180–1189.
22. Rosenwald, A., Alizadeh, A.A., Widhopf, G. et al.: Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J. Exp. Med., 194, 2001, s. 1639–1647.
23. Sanz, L., Garcia-Marco, J.A., Casanova, B. et al.: Bcl-2 family gene modulation during spontaneous apoptosis of B-chronic lymphocytic leukemia cells. Biochemical and Biophysical Research Communications, 315, 2004, s. 562–567.
24. Schweighoffer, E., Vanes, L., Mathiot, A., Nakamura, T., Tybulewicz, V.L.: Unexpected requirement for ZAP-70 in pre-B cell development and allelic exclusion. Immunity, 18, 2003, s. 523–533.
25. Wiestner, A., Rosenwald, A., Barry, T.S. et al.: ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome and distinct gene expression profile. Blood, 101, 2003, s. 4944–4951.
26. Zhang, J., Siraganian, R.P.: CD45 is essential for Fc epsilon RI signaling by ZAP-70, but not Syk, in Syk-negative mast cells. J. Immunol. 163, 1999, s. 2508–2516.
Štítky
Anatomical pathology Forensic medical examiner ToxicologyČlánok vyšiel v časopise
Czecho-Slovak Pathology
2009 Číslo 2
Najčítanejšie v tomto čísle
- New Trends in Diagnostics and Classification of Breast Carcinoma
- Immunohistochemical Detection of ZAP-70 Protein and its Importance in the Diagnostics of B-CLL
- Our Experience in Using Fluorescence in situ Hybridization FISH-Uro Vysion in Diagnostics of Urothelial Carcinoma
- PAG: A POTENTIAL TUMOUR SUPPRESSOR AND HOW IT ALL STARTED. FROM IMMUNE SIGNALLING TO NEOPLASTIC TRANSFORMATION